PL2036575T3 - Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością - Google Patents

Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością

Info

Publication number
PL2036575T3
PL2036575T3 PL07425563T PL07425563T PL2036575T3 PL 2036575 T3 PL2036575 T3 PL 2036575T3 PL 07425563 T PL07425563 T PL 07425563T PL 07425563 T PL07425563 T PL 07425563T PL 2036575 T3 PL2036575 T3 PL 2036575T3
Authority
PL
Poland
Prior art keywords
obesity
pharmaceutical compositions
oral use
treating patients
patients affected
Prior art date
Application number
PL07425563T
Other languages
English (en)
Inventor
Guido Vandoni
Heny Cassia Zaniboni
Original Assignee
Mader S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mader S R L filed Critical Mader S R L
Publication of PL2036575T3 publication Critical patent/PL2036575T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07425563T 2007-09-12 2007-09-12 Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością PL2036575T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07425563A EP2036575B1 (en) 2007-09-12 2007-09-12 Pharmaceutical compositions for oral use for treating patients affected by obesity

Publications (1)

Publication Number Publication Date
PL2036575T3 true PL2036575T3 (pl) 2011-02-28

Family

ID=38983405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07425563T PL2036575T3 (pl) 2007-09-12 2007-09-12 Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością

Country Status (10)

Country Link
US (1) US20100221326A1 (pl)
EP (1) EP2036575B1 (pl)
JP (1) JP2010539137A (pl)
AT (1) ATE477820T1 (pl)
AU (1) AU2008300030A1 (pl)
CA (1) CA2698882A1 (pl)
DE (1) DE602007008567D1 (pl)
ES (1) ES2350798T3 (pl)
PL (1) PL2036575T3 (pl)
WO (1) WO2009034171A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100958197B1 (ko) 2008-02-20 2010-05-14 (주)국전약품 올리스타트를 포함하는 약학적 조성물 및 이의 제조 방법
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
CN108785272B (zh) * 2018-09-04 2019-04-09 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2201272C2 (ru) * 1997-02-05 2003-03-27 Ф.Хоффманн-Ля Рош Аг Применение ингибиторов желудочно-кишечной липазы
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
WO2003009840A1 (en) * 2001-07-24 2003-02-06 Lonza Ag Composition comprising at least one lipase inhibitor and carnitine
WO2003047531A2 (en) * 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
WO2003090742A1 (en) * 2002-04-26 2003-11-06 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a lipase inhibitor and glucomannan
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity

Also Published As

Publication number Publication date
EP2036575B1 (en) 2010-08-18
JP2010539137A (ja) 2010-12-16
DE602007008567D1 (de) 2010-09-30
AU2008300030A1 (en) 2009-03-19
CA2698882A1 (en) 2009-03-19
WO2009034171A1 (en) 2009-03-19
ATE477820T1 (de) 2010-09-15
US20100221326A1 (en) 2010-09-02
ES2350798T3 (es) 2011-01-27
EP2036575A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
IL195571A0 (en) Compounds for the treatment of periodontal disease
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
IL205671A0 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
IL186578A0 (en) Compositions for treatment of neovascularization diseases
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
TN2011000291A1 (en) Purine compounds
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
EP2131780A4 (en) NEEDLE UNIT FOR ENDODONTIC TREATMENT
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
MX2011011618A (es) Agentes terapeuticos 713.
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
PL2036575T3 (pl) Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
DE602008002598D1 (en) Cyclohexylderivate
EP2216039A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ANXIETY
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
BRPI1008207A2 (pt) "composição farmacêutica para tratamento de efeitos colateriais por administração de spiegelmers."
HU0500145D0 (en) Composition for the treatment of oral diseases